128 related articles for article (PubMed ID: 37714801)
1. Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to drug-drug interactions.
González-Gómez Á; Caro-Teller JM; González-Barrios I; Castro-Frontiñán A; Rodríguez-Quesada PP; Ferrari-Piquero JM
Farm Hosp; 2024; 48(2):70-74. PubMed ID: 37714801
[TBL] [Abstract][Full Text] [Related]
2. [Translated article] Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to DDIs.
González-Gómez Á; Caro-Teller JM; González-Barrios I; Castro-Frontiñán A; Rodríguez-Quesada PP; Ferrari-Piquero JM
Farm Hosp; 2024; 48(2):T70-T74. PubMed ID: 37953113
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation.
Kwok WC; Tam TCC; Ho JCM; Lam DCL; Ip MS; Ho PL
Int J Chron Obstruct Pulmon Dis; 2024; 19():77-86. PubMed ID: 38222320
[TBL] [Abstract][Full Text] [Related]
4. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
5. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases.
Liu TH; Wu JY; Huang PY; Hsu WH; Chuang MH; Tsai YW; Lai CC; Huang CY
Expert Rev Anti Infect Ther; 2024; 22(1-3):121-128. PubMed ID: 37965890
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States.
Carlson J; Foos V; Kasle A; Mugwagwa T; Draica F; Lee Wiemken T; Nguyen JL; Cha-Silva A; Migliaccio-Walle K; Dzingina M
Value Health; 2024 Feb; 27(2):164-172. PubMed ID: 38043712
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
Zur M; Peselev T; Yanko S; Rotshild V; Matok I
Antiviral Res; 2024 Jan; 221():105768. PubMed ID: 38056602
[TBL] [Abstract][Full Text] [Related]
9. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study.
Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB
J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
Denning K; Sheppard J; Carico R
J Am Pharm Assoc (2003); 2024; 64(2):530-534. PubMed ID: 38151202
[TBL] [Abstract][Full Text] [Related]
12. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
Guzmán Cordero C; Saez-Torres de Vicente M
Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
[TBL] [Abstract][Full Text] [Related]
13. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M
Catlin NR; Bowman CJ; Campion SN; Cheung JR; Nowland WS; Sathish JG; Stethem CM; Updyke L; Cappon GD
Reprod Toxicol; 2022 Mar; 108():56-61. PubMed ID: 35101563
[TBL] [Abstract][Full Text] [Related]
14. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
15. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
[TBL] [Abstract][Full Text] [Related]
16. Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting.
Mutoh Y; Umemura T; Nishikawa T; Kondo K; Nishina Y; Soejima K; Noguchi Y; Bando T; Ota S; Shimahara T; Hirota S; Hagimoto S; Takei R; Fukihara J; Sasano H; Yamano Y; Yokoyama T; Kataoka K; Matsuda T; Kimura T; Ichihara T; Kondoh Y
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992519
[TBL] [Abstract][Full Text] [Related]
17. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.
Park JJ; Kim H; Kim YK; Lee SS; Jung E; Lee JS; Lee J
J Korean Med Sci; 2023 Oct; 38(42):e347. PubMed ID: 37904658
[TBL] [Abstract][Full Text] [Related]
20. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
Jang YR; Oh Y; Kim JY
J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]